Aktis Oncology, Inc.

$15.73$0.00 (0%)

Estimate

EPS

-1.32

Beta

0.071

Growth

Revenue, YoY

111.37%

Net income, YoY

-33.58%

FCF, YoY

-23.34%

Forecast

EPS (FWD)

-2.148

About the company

Ticker

AKTS

ISIN

US00973N1028

Country

United States of America

Sector (GICS)

Information Technology

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Frequently asked questions

What sector does Aktis Oncology, Inc. (AKTS) operate in?

Aktis Oncology, Inc. belongs to the Information Technology sector and operates in the Biotechnology industry.

What is Aktis Oncology, Inc. (AKTS) current stock price?

As of the latest data, Aktis Oncology, Inc. stock price is $15.73, with a previous close of $15.73.

What is Aktis Oncology, Inc. (AKTS) current market capitalization?

Aktis Oncology, Inc. market cap is approximately 845.44 million.

What is Aktis Oncology, Inc. (AKTS) Earnings Per Share (EPS)?

The trailing EPS is -$1.32, and the forward EPS is -$2.15.

What is Aktis Oncology, Inc. (AKTS) EBITDA?

Aktis Oncology, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -28.02 million.

Does Aktis Oncology, Inc. (AKTS) pay dividends?

No. Aktis Oncology, Inc. does not pay a dividend.

How did Aktis Oncology, Inc. (AKTS) perform in its most recent earnings report?

In the last report (June 30, 2026), Aktis Oncology, Inc. posted an EPS surprise of 0% and a revenue surprise of 30.99%.

When is Aktis Oncology, Inc. (AKTS) next earnings report?

Aktis Oncology, Inc. is expected to release its next earnings report on September 30, 2026.

What is Aktis Oncology, Inc. (AKTS) beta (volatility) score?

Aktis Oncology, Inc. has a beta of 0.071, indicating lower volatility than the overall market.